News


  • 14 December 2016

    Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer

    Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer

    Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, for intramural preclinical and clinical research.

  • 14 December 2016

    Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index

    Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index

    learside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has been selected by NASDAQ for inclusion in the NASDAQ Biotechnology Index® (NBI). The annual re-ranking of the NBI will become effective at market open on  Monday, December 19, 2016 .

  • 09 December 2016

    Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock

    Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock

    Clearside Biomedical , Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of  $75 million  of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional  $11.25 million  of shares of common stock at the public offering price, less the underwriting discount.

  • 07 December 2016

    Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock

    Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock

    Clearside Biomedical , Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of  $75 million  of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional  $11.25 million  of shares of common stock at the public offering price, less the underwriting discount.

  • 16 November 2016

    Epic Sciences Validates Single CTC Sequencing, Identifies Clonal Heterogeneity in Metastatic Cancer

    Epic Sciences Validates Single CTC Sequencing, Identifies Clonal Heterogeneity in Metastatic Cancer

    Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells (CTC) and demonstrated clinical feasibility in metastatic prostate cancer patients (mCRPC).  In addition to profiling genome wide copy number variation (CNV) from single cells, the authors also validated the ability to characterize the extent of genomic instability within individual CTCs.

  • 15 November 2016

    Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus

    Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data showing that the combination of its CNS-selective GABAA modulator ganaxolone and diazepam administered intravenously (IV) produced a synergistic effect in blocking pilocarpine-induced seizures in a benzodiazepine refractory model of status epilepticus (SE). 

  • 15 November 2016

    Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata in Diabetic Macular Edema

    Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata in Diabetic Macular Edema

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 1/2 clinical trial (the “HULK” trial) of Zuprata™, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, for the treatment of diabetic macular edema (“DME”).

  • 10 November 2016

    Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

    Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the third quarter ended September 30, 2016. In addition, the Company provided a pipeline update as well as a review of upcoming milestones. As of September 30, 2016, Syndax had $115.6 million in cash, cash equivalents and short-term investments.

  • 10 November 2016

    NovaMedica prepares to launch the new drug development laboratories

    NovaMedica prepares to launch the new drug development laboratories

    Russian pharmaceutical company NovaMedica launches R&D laboratories as part of its Technology Center project for the development and pilot production of innovative drugs. The facilities are designed to address the most challenging scientific tasks based on the state-of-the-art platforms incorporating nanotechnologies. The project investment totals $15m.                                                   

  • 10 November 2016

    ReVision Optics Raises $32 Million to Fund Expansion of U.S. Commercialization of Raindrop Near Vision Inlay

    ReVision Optics Raises $32 Million to Fund Expansion of U.S. Commercialization of Raindrop Near Vision Inlay

    ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that it has raised $32 million in an equity financing that was led by JJDC, with pro rata participation or better by current investors Canaan Partners, Domain Associates, InterWest Partners and ProQuest Investments.